Research Council

The purpose of the Division 55 Research Council is to promote dissemination of high-quality, evidence-based research related to the causes of and treatments for mental illness and substance use disorders. The task of the council is to keep abreast of the clinical research relevant to the specialty and highlight articles and issues of interest. It encourages the critical reading of research and monitors ongoing trends in clinical psychopharmacology with an informed understanding of the needs of the populations served by psychologists specially trained in clinical psychopharmacology. The Research Council posts relevant recent articles on this website, disseminates relevant information on clinical psychopharmacology to the membership via the Division 55 listserv, and acts as consultant to Division 55 and other APA Divisions, and as a potential advisory resource to inform APA policy decisions on matters related to psychologists who have an interest in the application of psychopharmacological principles within their practice or those specially trained psychologists who have or intend to pursue prescription privileges. Finally, the Research Council offers its members’ expertise and knowledge base as speakers on topics related to psychopharmacology and as a resource to SPTA committees in states that are in the process of or contemplating pursuing RxP legislation.

Erinn C. Cameron, MA
Cannabis Delivery Method Usage Patterns and Preferences for Women with Chronic Pain

Michelle Woods, MS, MA
Increased Amount of Medical Cannabis Use Per Week is Associated with Less Memory Dysfunction

Matheus Teles G. Araujo, BS
International Prescriptive Psychology: A Recent History
Panel Member: Prescriptive Authority Around the Globe
(Chair: Beth N. Rom-Rymer, PhD, MA)

Morgan Ferris-Johnston, MA, MSCP
Panel Member: Predoctoral Education and Training in Clinical Psychopharmacology: What Have We Learned?
(Chair: Gerardo R. Rodriguez-Menendez, PhD, MSCP, ABPP)

Below you will find a list of current articles and citations that have been reviewed by the council. Members of ASAP/Division 55 are encouraged to submit articles for inclusion on the listing. Inclusion of an articles or citation in this listing does not indicate support or endorsement of the council for the contents of the article but rather points out articles of interest and worthy of individual review and consideration.

• Clozapine Cardiotoxicity: A Compendium for Psychiatry Cliniciansopens in new window
• Asmara, K. E., Fèvec, B., Collea, R., Gressiera, F., Vievard, A., Trabadob, S. et al. 2018. Early weight gain predicts later weight gain in depressed patients treated with antidepressants: Findings from the METADAP cohortopens in new window. Journal of Affective Disorders 241, 22–28.
  
• Benson, K., Woodlief, D.T., Flory, K., Siceloff, E.R., Coleman, K. & Lamont, A. 2018. Is ADHD, Independent of ODD, Associated With Whether and Why College Students Misuse Stimulant Medication?opens in new window Experimental and Clinical Psychopharmacology, 26, 5, 476–487. https://dx.doi.org/10.1037/pha0000202
  
• Cipriani, A. Furukawa, T.A., Salanti, G., Chaimani, A., Atkinson, L.Z., Ogawa, Y. et al. 2018. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysisopens in new window Lancet, 391, 1357–66 https://dx.doi.org/10.1016/S0140-6736(17)32802-7
• Davies, J. 2018. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based?opens in new window Addictive Behaviors, https://doi.org/10.1016/j.addbeh.2018.08.027
• Lopez-Leon, S., Lopez-Gomez, M.I., Warner, B. & Ruiter-Lopez, L. Psychotropic medication in children and adolescents in the United States in the year 2004 vs 2014.opens in new window 2018. DARU Journal of Pharmaceutical Sciences 26, 5–10. https://doi.org/10.1007/s40199-018-0204-6
• Maust, D.T., Kim, H.M., Chiang, C. Kales, H.C. 2018. Association of the Centers for Medicare & Medicaid Services’ National Partnership to Improve Dementia Care With the Use of Antipsychotics and Other Psychotropics in Long-term Care in the United States From 2009 to 2014.opens in new window JAMA Intern Med.,178, 5, 640-647. doi:10.1001/jamainternmed.2018.0379
• Rheker, J., Rief, W., Doering, B.K. & Winkler, A. 2018. Assessment of Adverse Events in Clinical Drug Trials: Identifying Amitriptyline’s Placebo- and Baseline-Controlled Side Effects.opens in new window Experimental and Clinical Psychopharmacology, 26, 3, 320–326. https://dx.doi.org/10.1037/pha0000194
• Sharon, G., Sampson,T.R., Geschwind, D.H. & Mazmanian, S.K.. 2016. The Central Nervous System and the Gut Microbiome.opens in new window Cell, 167, 915-932.
• Streck, J.M., Ochalek, T.A., Badger, G.J. & Sigmon, S.C. 2018. Interim Buprenorphine Treatment During Delays to Comprehensive Treatment: Changes in Psychiatric Symptoms.opens in new window Experimental and Clinical Psychopharmacology, 26, 4, 403–409. https://dx.doi.org/10.1037/pha0000199
• Zeier, Z. , L.L., Kalin, N.H., Rodriguez, C.I., McDonald, W.M., Widge, A.S., & Nemeroff, C.B. 2018. Clinical Implementation of Pharmacogenetic Decision Support Tools for Antidepressant Drug Prescribingopens in new window. Am. J.  Psychiatry, 175, 9, 873-886.
• Hughes, P. M., Annis, I. E., McGrath, R. E., & Thomas, K. C. (2023). Psychotropic medication prescribing across medical providers, 2016–2019. Psychiatric Services, appi.ps.20230156. https://doi.org/10.1176/appi.ps.20230156opens in new window
• Hughes, P. M., Graaf, G., Gigli, K. H., deJong, N. A., McGrath, R. E., & Thomas, K. C. (2024a). Scope-of-practice expansions associated with reduced racial disparities in pediatric mental health care. Community Mental Health Journal. https://doi.org/10.1007/s10597-024-01310-6opens in new window
• Hughes, P. M., Graaf, G., Gigli, K. H., deJong, N., McGrath, R. E., & Thomas, K. C. (2024b). Pediatric Mental Health Care and Scope-of-Practice Expansions.
• Hughes, P. M., McGrath, R. E., & Thomas, K. C. (2023). Evaluating the impact of prescriptive authority for psychologists on the rate of deaths attributed to mental illness. Research in Social and Administrative Pharmacy, 19(4), 667–672. https://doi.org/10.1016/j.sapharm.2022.12.006opens in new window
• Hughes, P. M., McGrath, R. E., & Thomas, K. C. (2024). Simulating the impact of psychologist prescribing authority policies on mental health prescriber shortages. Professional Psychology: Research and Practice, 55(2), 140–150. https://doi.org/10.1037/pro0000560opens in new window
• Hughes, P. M., Niznik, J. D., McGrath, R. E., Tak, C. R., Christian, R. B., Sleath, B. L., & Thomas, K. C. (2024a). Assessing the safety and efficacy of prescribing psychologists in New Mexico and Louisiana. American Psychologist. https://doi.org/10.1037/amp0001373opens in new window
• Hughes, P. M., Niznik, J. D., McGrath, R. E., Tak, C. R., Christian, R. B., Sleath, B. L., & Thomas, K. C. (2024b). Demographics and clinical characteristics of patients of prescribing psychologists, psychiatrists, and primary care physicians. American Psychologist. https://doi.org/10.1037/amp0001352opens in new window
• Hughes, P. M., Phillips, D. C., & Fagan, E. B. (2023). Prescribing psychologists: Forgotten providers in the battle against opioid use disorder. Addiction. https://doi.org/10.1111/add.16204opens in new window
• Hughes, P. M., Phillips, D. C., McGrath, R. E., & Thomas, K. C. (2023). Examining psychologist prescriptive authority as a cost-effective strategy for reducing suicide rates. Professional Psychology: Research and Practice, 54(4), 284–294. https://doi.org/10.1037/pro0000519opens in new window
• Hughes, P. M., Warner, D. N., Phillips, D. C., McGrath, R. E., & Thomas, K. C. (2024). Assessing psychologists’ intentions to become licensed prescribers in Pennsylvania using the theory of planned behavior. Professional Psychology: Research and Practice, 55(4), 324–335. https://doi.org/10.1037/pro0000575opens in new window